The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
The formulation is backed by over 80 clinical trials and 200 scientific publications
The move is expected to be crucial during health crises
Subscribe To Our Newsletter & Stay Updated